Abstract:To identify protein biomarkers capable of early prediction regarding the distinguishing malignant pleural effusion (MPE) from benign pleural effusion (BPE) in patients with lung disease. A four-dimensional data independent acquisition (4D-DIA) proteomic was performed to determine the differentially expressed proteins in samples from 20 lung adenocarcinoma MPE and 30 BPE. The significantly differential expressed proteins were selected for Gene Ontology (GO) enrichment and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis. Protein biomarkers with high capability to discriminate MPE from BPE patients were identified by Random Forest (RF) algorithm prediction model, whose diagnostic and prognostic efficacy in primary tumors were further explored in public datasets, and were validated by ELISA experiment. 50 important proteins (30 up-regulated and 20 down-regulated) were selected out as potential markers to distinguish the MPE from BPE group. GO analysis revealed that those proteins involving the most important cell component is extracellular space. KEGG analysis identified the involvement of cellular adhesion molecules pathway. Furthermore, the Area Under Curve (AUC) of these proteins were ranged from 0.717 to 1.000,with excellent diagnostic properties to distinguish the MPE. Finally, significant survival and gene and protein expression analysis demonstrated BPIFB1, DPP4, HPRT1 and ABI3BP had high discriminating values. Significance We performed a 4D-DIA proteomics to determine the differentially expressed proteins in pleural effusion samples from MPE and BPE. Some potential protein biomarkers were identified to distinguish the MPE from BPE patients., which may provide helpful diagnostic and therapeutic insights for lung cancer. This is significant because the median survival time of patients with MPE is usually 4–12 months, thus, it is particularly important to diagnose MPE early to start treatments promptly. The most common causes of MPE are lung cancers, while pneumonia and tuberculosis are the main causes of BPE. If more diagnostic markers could be identified periodically, there would be an important significance to clinical diagnose and treatment with drugs in lung cancer patients.

Investigation of biochemical markers for the differential diagnosis between lung cancer and lung infection

Differential Proteome Profiling of Pleural Effusions from Lung Cancer and Benign Inflammatory Disease Patients

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Significance of serum and pleural effusion levels of related factors in differential diagnosis of tuberculosis and malignant tumor

The Diagnostic Value of MCP-1 and RANTES in Tuberculosis and Malignant Pleural Effusion

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients

Quantitative proteomics revealed protein biomarkers to distinguish malignant pleural effusion from benign pleural effusion

Metabolomic analysis based on 1H-nuclear magnetic resonance spectroscopy metabolic profiles in tuberculous, malignant and transudative pleural effusion

Use of tumor markers in distinguishing lung adenocarcinoma-associated malignant pleural effusion from tuberculous pleural effusion

Simultaneous detection of 10 cancer-associated amino acids and polyamines by high-performance liquid chromatography-high resolution mass spectrometry in pleural effusion cells obtained from lung adenocarcinoma patients

The expression levels of VEGF and ICAM-1 in pleural effusion

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

Changes Of Tumor Markers And C Reactive Protein In Different Status Of Lung Cancer

Combined Detection of Carcinoembryonic Antigen and C-reactive Protein in Identifying Benign and Malignant Pleural Effusion

Clinical Significance of Combined Detection of CEA, CYFRA21-1,CA19-9 and Fer in Differential Diagnosis of Benign Pleural Effusion and Malignant Pleural Effusion

The investigation of the volatile metabolites of lung cancer from the microenvironment of malignant pleural effusion

Proteomic study of benign and malignant pleural effusion

Integrated Semi-Targeted Metabolomics Analysis Reveals Distinct Metabolic Dysregulation in Pleural Effusion Caused by Tuberculosis and Malignancy.

Metabonomic Classification and Detection of Small Molecule Biomarkers of Malignant Pleural Effusions

A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion

Study on the significance of tumor markers in bronchoalveolar lavage fluid for diagnosis of primary lung cancer